Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
ASCOT-LLA Trial
Introduction
Click here to download slides for ASCOT-LLA.
Overview
Overview
Hypertensive patients (n=10305) with total cholesterol < 251 mg/dL were randomly assigned to atorvastatin 10 mg daily and a significant reduction in non-fatal MI, fatal CHD and stoke (fatal and non-fatal) was noticed. No significant difference was observed on all-cause mortality. The trial was stopped earlier than expected of 5 years because of beneficial treatment[1].
References
References
- ↑ Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M; et al. (2003). “Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial”. Lancet. 361 (9364): 1149–58. doi:10.1016/S0140-6736(03)12948-0. PMID 12686036. Review in: ACP J Club. 2003 Nov-Dec;139(3):57
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]